Evaluating PET/CT Imaging for Gastric Cancer Treatment Assessment
The Role of 18F-FDG & 68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastatic
This study is testing if special PET/CT scans can help doctors see how well conversion therapy is working for people with advanced gastric cancer that has spread to the lining of the abdomen.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06597526 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effectiveness of 18F-FDG and 68Ga-FAPI PET/CT imaging in assessing the outcomes of conversion therapy in patients with gastric cancer that has spread to the peritoneum. Participants will undergo a series of PET/CT scans before and after conversion therapy to monitor disease progression and treatment efficacy. The study aims to collect detailed patient data, including demographics and clinical history, to better understand the prognostic value of these imaging techniques in this specific cancer population.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically confirmed gastric adenocarcinoma and peritoneal metastases requiring diagnostic laparoscopy.
Not a fit: Patients with distant metastases beyond the peritoneum or those with severe mental health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the assessment of treatment efficacy and prognosis for patients with gastric cancer and peritoneal metastasis.
How similar studies have performed: While the use of PET/CT imaging in cancer assessment is established, the specific combination of 18F-FDG and 68Ga-FAPI in this context is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions 2. Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction 3. Patients voluntarily enrolled in this study by signing an informed consent form 4. Age ≥ 18 years 5. Eastern Cooperative Oncology Group (ECOG) score ≤ 2, 6. Expected life expectancy ≥ 3 months 7. Adequate organ and bone marrow function 8. Willingness to adhere to the study protocol and follow-up programme Exclusion Criteria: 1. Signs of distant metastases other than peritoneal metastases at enrolment 2. Pregnant or breastfeeding women. 3. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix 4. Severe mental disease, uncontrolled epilepsy, or central nervous system disease
Where this trial is running
Shanghai, Shanghai Municipality
- Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Jiajia Hu
- Email: jiajiahu@shsmu.edu.cn
- Phone: 0086-13524945287
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.